The landscape of advanced/metastatic NSCLC has changed dramatically with the approval of immunotherapies and targeted agents in recent years. After metastatic disease, early-stage NSCLC has become a new testing ground for these therapies. Most key players are in the race to position their drugs in this hitherto unexplored territory where surgery, radiotherapy (RT), or chemoradiation (ChemoRT) has remained the mainstay of treatment.
Let’s together explore how early-stage NSCLC is shaping up with the entrenchment of new therapies and what new questions have emerged with this paradigm shift. FutureBridge’s Oncology Analysts in this webinar will cover the:
Share your focus area or question to engage with our Analysts through the Business Objectives service.Submit My Business Objective
Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.